Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc. (APDN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
apdn · stock forecast · 4 analysts (3M) · FMP · updated Mar 29, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.50
Consensus
$1.50
-55.9% upside
Low
$1.50
Median: $1.5 · Last Close: $3.40
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.40 | ↑ 0.00% |
1-day model range: $3.29–$3.51. Peak: $3.51 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · APDN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-06-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-02-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-12-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-03-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Applied DNA Sciences, Inc. (APDN) stock. Of the recent 30 rating actions, 2 were upgrades and 0 were downgrades. 4 analysts currently cover APDN.
Analyst Recommendation Trends
APDN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$19M
↑ 433.5% YoY
Revenue Next Year
$9M
↓ 51.9% YoY
EPS This Year
$-23.80
EPS Next Year
$-10.98
↓ 53.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast APDN EPS of $-23.80 for the current fiscal year, based on estimates from 1 analysts. The APDN revenue forecast is $19M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APDN stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APDN price target is $1.50 (-55.9% upside), with an analyst consensus of Buy.
The APDN short-term stock prediction for tomorrow is $3.40 (+0.00%).
Applied DNA Sciences, Inc. trades on NASDAQ under the ticker APDN. The APDN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
APDN forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month APDN price target is $1.50, with a high forecast of $1.50 and a low of $1.50. The median price target is shown in the chart above when available. This implies -55.9% potential upside from the current price of $3.40.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.